论文部分内容阅读
目的探讨联合检测血清癌抗原CA125、AFP和CA199对卵巢癌的临床诊断价值。方法卵巢癌患者59例,卵巢良性病变49例和健康妇女50例。用电化学发光免疫测定CA125、AFP和CA199含量。结果与良性病变组和健康妇女组相比,卵巢癌患者血清CA125、AFP和CA199的含量和阳性率明显升高,三项标志物的阳性检出率分别是79.67%、47.4%和44.0%,C125和AFP联检的阳性率为89.8%,CA125和CA199联检的阳性率为81.3%,三者联合检测阳性率为93.2%。结论联合检测CA125、AFP和CA199对卵巢癌的诊断具有重要临床价值。
Objective To investigate the clinical value of combined detection of serum CA125, AFP and CA199 in ovarian cancer. Methods 59 patients with ovarian cancer, benign ovarian lesions in 49 cases and 50 healthy women. The contents of CA125, AFP and CA199 were determined by electrochemiluminescence immunoassay. Results The positive rate of serum CA125, AFP and CA199 in patients with ovarian cancer was significantly higher than that in benign lesions and healthy women. The positive rates of the three markers were 79.67%, 47.4% and 44.0% respectively, The positive rate of C125 and AFP joint examination was 89.8%, the positive rate of CA125 and CA199 joint examination was 81.3%, and the positive rate of combined detection of the three was 93.2%. Conclusion Combined detection of CA125, AFP and CA199 has important clinical value in the diagnosis of ovarian cancer.